Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Oct;68(4):493-501.
doi: 10.1111/j.1365-2125.2009.03484.x.

Proposals for model-based paediatric medicinal development within the current European Union regulatory framework

Efthymios Manolis  1 , Gérard Pons
Affiliations

Proposals for model-based paediatric medicinal development within the current European Union regulatory framework

Efthymios Manolis et al. Br J Clin Pharmacol. 2009 Oct.

Abstract

The new paediatric European Union (EU) regulation and the consequent demand for paediatric studies on one hand and the ethical need for minimizing the burden of studies in children on the other hand necessitate optimal techniques in the assessment of safety/efficacy and use of drugs in children. Modelling and simulation (M&S) is one way to circumvent some difficulties in developing medicinal products in children. M&S allows the quantitative use of sparse sampling, characterization and prediction of pharmacokinetics/pharmacodynamics (PK/PD), extrapolation from adults to children, interpolation between paediatric age subsets, optimal use of scientific literature and in vitro/preclinical data. Together, industry, academia and regulators recognize the usefulness of modelling and simulation in this setting. However, even if M&S is an emerging science, its integration in the EU regulatory decision making is for the time being deficient and M&S expertise is concentrated in big pharmaceutical companies and academic institutions. The European Medicines Agency, acknowledging all the above conditions, organized and hosted a Workshop on Modelling in Paediatric Medicines. The article presents the personal views of the authors on the issues presented and discussed in the workshop.We attempt to identify the regulatory framework for the use of M&S in paediatric medicinal development and to make proposals for model-based paediatric medicinal development. The objective is to open the discussion between industry, academia, paediatricians and regulators on the optimal use of M&S in paediatric medicinal development.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Paediatric study decision tree with identified scenarios
Figure 2
Figure 2
Modelling and simulation role in bridging adult and paediatric data
Figure 3
Figure 3
Modelling and simulation role in developing a new paediatric formulation of an already authorized in children medicinal product
See this image and copyright information in PMC

References

    1. EMEA. EMEA Workshop on Modelling in Paediatric Medicines. London: EMEA; pp. 14–15. April 2008 Available at http://www.emea.europa.eu/htms/human/paediatrics/workshops.htm (last accessed 1 May 2009.
    1. Holford NHG, Kimko HC, Monteleone JPR, Peck CC. Simulation of Clinical Trials. Annu Rev Pharmacol Toxicol. 2000;40:209–34. - PubMed
    1. Guideline on Reporting the Results of Population Pharmacokinetic Analyses. CHMP/EWP/185990/06. Available at http://www.emea.europa.eu/pdfs/human/ewp/18599006enfin.pdf (last accessed 1 May 2009.
    1. Guidance for Industry Population Pharmacokinetics. Available at http://www.fda.gov/CDER/guidance/1852fnl.pdf (last accessed 1 May 2009.
    1. Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol. 2000;40:67–95. - PubMed